{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:15:22Z","timestamp":1794683722256,"version":"4.9.1"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2025ZNSFSC0784"],"award-info":[{"award-number":["2025ZNSFSC0784"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2025,8,12]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Question<\/jats:title>\n                    <jats:p>How effective is pharmacogenomic (PGx)-guided antidepressant treatment compared with treatment-as-usual (TAU) in major depressive disorder (MDD), and how do ethnicity, disease severity and genetic panel scope influence outcomes?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and analysis<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis comprised 13 randomised controlled trials (2013\u20132024) comparing PGx-guided therapy with TAU in MDD. PubMed, Ovid Embase, Ovid Medline, Ovid PsycINFO and the Cochrane Library were searched up to December 2024. Outcomes included response and remission rates at 8 and 12 weeks. Subgroup analyses examined ethnicity and MDD severity. Cumulative meta-analyses assessed gene panel size. The pooled risk ratios (RRs) with 95% CIs were calculated to estimate the overall effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>PGx-guided treatment significantly improved response rates at 8 weeks (RR 1.23, 95% CI 1.05 to 1.43) and 12 weeks (RR 1.29, 95% CI 1.17 to 1.43). Remission was significant at 8 weeks (RR 1.37, 95% CI 1.19 to 1.57) but not at 12 weeks (RR 1.56, 95% CI 0.93 to 2.61). Benefits appeared stronger in the Asian country subgroup compared with non-Asian country subgroup (interaction p=0.02), but this requires validation due to the smaller Asian country sample size. No significant subgroup differences were observed between the MDD not-specified and MDD difficult-to-treat subgroups, despite the latter demonstrating significant improvements in both response and remission rates with PGx-guided treatment compared with TAU at 8 weeks. Cumulative analyses showed effect sizes plateaued, with broader panels offering minimal incremental gains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PGx-guided treatment seems to offer moderate benefits for antidepressant efficacy, with potential advantages in Asian and difficult-to-treat subgroups. Genetic and ethnic variability in drug metabolism underscores the need for population-specific approaches. While multigene panels show clinical benefits plateau, suggesting cost-benefit optimisation is critical. Future research should address adverse events, the cost\u2010effectiveness of expanded panels, long\u2010term remission outcomes and treatment efficacy across more precisely stratified disease severity levels to maximise clinical relevance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024570014.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2025-301726","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T02:05:19Z","timestamp":1756173919000},"page":"e301726","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative effectiveness of pharmacogenomic-guided versus unguided antidepressant treatment in major depressive disorder: new insights from subgroup and cumulative meta-analyses"],"prefix":"10.1136","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-7531","authenticated-orcid":false,"given":"Yuan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3090-8912","authenticated-orcid":false,"given":"Yiyuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Chengdu Eighth People\u2019s Hospital, Geriatric Hospital of Chengdu Medical College, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2749-006X","authenticated-orcid":false,"given":"Yazhu","family":"Zou","sequence":"additional","affiliation":[{"name":"Sichuan Provincial Center for Mental Health, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5869-7600","authenticated-orcid":false,"given":"Yu","family":"Ye","sequence":"additional","affiliation":[{"name":"Sichuan Provincial Center for Mental Health, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9174-1968","authenticated-orcid":false,"given":"Fugui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Sichuan Provincial Center for Mental Health, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5004-9422","authenticated-orcid":false,"given":"Zuxing","family":"Wang","sequence":"additional","affiliation":[{"name":"Sichuan Provincial Center for Mental Health, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1780-6828","authenticated-orcid":false,"given":"Jian","family":"Qiu","sequence":"additional","affiliation":[{"name":"Sichuan Provincial Center for Mental Health, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1973-5923","authenticated-orcid":false,"given":"Zhili","family":"Zou","sequence":"additional","affiliation":[{"name":"Sichuan Provincial Center for Mental Health, Sichuan Provincial People\u2019s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China"},{"name":"Key Laboratory of Psychosomic Medicine, Chinese Academy of Medical Sciences, Chengdu, Sichuan, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"2026010702311910000_28.1.e301726.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-023-00454-1"},{"key":"2026010702311910000_28.1.e301726.2","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1017\/S0033291719002812","article-title":"Towards personalising treatment: a systematic review and meta-analysis of face-to-face efficacy moderators of cognitive-behavioral therapy and interpersonal psychotherapy for major depressive disorder","volume":"49","author":"Whiston","year":"2019","journal-title":"Psychol Med"},{"key":"2026010702311910000_28.1.e301726.3","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20941"},{"key":"2026010702311910000_28.1.e301726.4","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.472","article-title":"Depressive disorders: Treatment failures and poor prognosis over the last 50 years","volume":"7","author":"Blackburn","year":"2019","journal-title":"Pharmacology Res & Perspec"},{"key":"2026010702311910000_28.1.e301726.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01488-3","article-title":"Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data","volume":"11","author":"Taliaz","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2026010702311910000_28.1.e301726.6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pnpbp.2018.05.007","article-title":"Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials","volume":"86","author":"Fabbri","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2026010702311910000_28.1.e301726.7","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/ph17070940","article-title":"Pharmacogenomics: A Genetic Approach to Drug Development and Therapy","volume":"17","author":"Qahwaji","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026010702311910000_28.1.e301726.8","unstructured":"Li KX , Loshak H . Pharmacogenomic testing in depression: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa (ON), 2020."},{"key":"2026010702311910000_28.1.e301726.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41398-021-01600-7","article-title":"Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis","volume":"11","author":"Virelli","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2026010702311910000_28.1.e301726.10","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2018-0142"},{"key":"2026010702311910000_28.1.e301726.11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2217\/pgs-2019-0157","article-title":"The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis","volume":"21","author":"Brown","year":"2020","journal-title":"Pharmacogenomics"},{"key":"2026010702311910000_28.1.e301726.12","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jad.2024.09.041","article-title":"Drug metabolizing enzymes pharmacogenetic variation-informed antidepressant therapy approach for common mental disorders: A systematic review and meta-analysis","volume":"367","author":"Santenna","year":"2024","journal-title":"J Affect Disord"},{"key":"2026010702311910000_28.1.e301726.13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.12443","article-title":"Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder","volume":"6","author":"Vos","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026010702311910000_28.1.e301726.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.05.063"},{"key":"2026010702311910000_28.1.e301726.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2017.09.024"},{"key":"2026010702311910000_28.1.e301726.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2019.01.003"},{"key":"2026010702311910000_28.1.e301726.17","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14195"},{"key":"2026010702311910000_28.1.e301726.18","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3389\/fnins.2019.00960","article-title":"Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study","volume":"13","author":"Shan","year":"2019","journal-title":"Front Neurosci"},{"key":"2026010702311910000_28.1.e301726.19","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2018.16.4.469"},{"key":"2026010702311910000_28.1.e301726.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial","volume":"17","author":"P\u00e9rez","year":"2017","journal-title":"BMC Psychiatry"},{"key":"2026010702311910000_28.1.e301726.21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41398-022-01963-5","article-title":"Correction: Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial","volume":"12","author":"Tiwari","year":"2022","journal-title":"Transl Psychiatry"},{"key":"2026010702311910000_28.1.e301726.22","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211015224"},{"key":"2026010702311910000_28.1.e301726.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.9805"},{"key":"2026010702311910000_28.1.e301726.24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/da.23029","article-title":"Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder","volume":"37","author":"Perlis","year":"2020","journal-title":"Depress Anxiety"},{"key":"2026010702311910000_28.1.e301726.25","first-page":"219","article-title":"A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder","volume":"16","author":"Winner","year":"2013","journal-title":"Discov Med"},{"key":"2026010702311910000_28.1.e301726.26","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283649b9a"},{"key":"2026010702311910000_28.1.e301726.27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.9758\/cpn.2015.13.2.150","article-title":"Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2026010702311910000_28.1.e301726.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.03.017"},{"key":"2026010702311910000_28.1.e301726.29","doi-asserted-by":"crossref","first-page":"111492","DOI":"10.1016\/j.jclinepi.2024.111492","article-title":"A brief note on the random-effects meta-analysis model and its relationship to other models","volume":"174","author":"McKenzie","year":"2024","journal-title":"J Clin Epidemiol"},{"key":"2026010702311910000_28.1.e301726.30","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/cpt.2748","article-title":"Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta\u2010Analysis of Prospective, Controlled Clinical Trials","volume":"112","author":"Brown","year":"2022","journal-title":"Clin Pharma and Therapeutics"},{"key":"2026010702311910000_28.1.e301726.31","doi-asserted-by":"crossref","first-page":"115102","DOI":"10.1016\/j.psychres.2023.115102","article-title":"Evaluating treatment outcomes in pharmacogenomic-guided care for major depression: A rapid review and meta-analysis","volume":"321","author":"Bunka","year":"2023","journal-title":"Psychiatry Res"},{"key":"2026010702311910000_28.1.e301726.32","doi-asserted-by":"crossref","DOI":"10.1136\/gpsych-2023-101050","article-title":"Effectiveness of pharmacogenomics on the response and remission of treatment-resistant depression: a meta-analysis of randomised controlled trials","volume":"36","author":"Cheng","year":"2023","journal-title":"Gen Psych"},{"key":"2026010702311910000_28.1.e301726.33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.euroneuro.2024.01.005","article-title":"Current level of evidence for improvement of antidepressant efficacy and tolerability by pharmacogenomic-guided treatment: A Systematic review and meta-analysis of randomized controlled clinical trials","volume":"81","author":"Milosavljevi\u0107","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"2026010702311910000_28.1.e301726.34","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1276410","article-title":"Efficacy and safety of pharmacogenomic-guided antidepressant prescribing in patients with depression: an umbrella review and updated meta-analysis","volume":"15","author":"Tesfamicael","year":"2024","journal-title":"Front Psychiatry"},{"key":"2026010702311910000_28.1.e301726.35","doi-asserted-by":"publisher","DOI":"10.1002\/CPT.2903"},{"key":"2026010702311910000_28.1.e301726.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"2026010702311910000_28.1.e301726.37","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.132"},{"key":"2026010702311910000_28.1.e301726.38","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","article-title":"Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17","volume":"69","author":"Li\u2010Wan\u2010Po","year":"2010","journal-title":"Brit J Clinical Pharma"},{"key":"2026010702311910000_28.1.e301726.39","article-title":"Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population","volume":"29","author":"Payan","year":"2015","journal-title":"Med J Islam Repub Iran"},{"key":"2026010702311910000_28.1.e301726.40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41398-020-01129-1","article-title":"Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19","volume":"11","author":"Koopmans","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2026010702311910000_28.1.e301726.41","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.80"},{"key":"2026010702311910000_28.1.e301726.42","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145712001459"},{"key":"2026010702311910000_28.1.e301726.43","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2174\/157016111796197233","article-title":"Gene-lifestyle and gene-pharmacotherapy interactions in obesity and its cardiovascular consequences","volume":"9","author":"Franks","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"2026010702311910000_28.1.e301726.44","doi-asserted-by":"crossref","first-page":"18008","DOI":"10.1038\/nrdp.2018.8","article-title":"Bipolar disorders","volume":"4","author":"Vieta","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2026010702311910000_28.1.e301726.45","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17111282"},{"key":"2026010702311910000_28.1.e301726.46","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01806-1"},{"key":"2026010702311910000_28.1.e301726.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.05.051"},{"key":"2026010702311910000_28.1.e301726.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0379-x"},{"key":"2026010702311910000_28.1.e301726.49","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124835"},{"key":"2026010702311910000_28.1.e301726.50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41397-022-00272-w","article-title":"A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges","volume":"22","author":"Sukri","year":"2022","journal-title":"Pharmacogenomics J"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2025-301726","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:31:59Z","timestamp":1767781919000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2025-301726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,25]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjment-2025-301726"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2025-301726","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}